Literature DB >> 15515013

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

Krittaya Sutheesophon1, Noriko Nishimura, Yukiko Kobayashi, Yutaka Furukawa, Mikihiko Kawano, Kouichi Itoh, Yasuhiko Kano, Hideshi Ishii, Yusuke Furukawa.   

Abstract

Inhibition of histone deacetylase (HDAC) is a novel strategy for the treatment of leukemias via restoration of aberrantly silenced genes. In this study, we conducted a detailed analysis of anti-leukemic effects of an HDAC inhibitor (HDI), depsipeptide (FK228), using myeloid leukemia cell lines HL-60 and K562. DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug. Upregulation of TNF-alpha was induced by depsipeptide in HL-60 and K562 cells, which expressed type I TNF receptors (TNF-RI). Depsipeptide activated caspases-8 and -10, which in turn cleave caspases-3 and -7, leading to apoptotic cell death in both cell lines. Anti-TNF-alpha neutralizing antibody and short interfering RNA (siRNA) against TNF-RI alleviated the activation of the caspase cascade and the induction of apoptosis, indicating the presence of an autocrine loop. Finally, we demonstrated that the enhanced production of TNF-alpha by depsipeptide was due to transcriptional activation of the TNF-alpha gene through hyperacetylation of histones H3 and H4 in its promoter region (-208 to +35). These results suggest that autocrine production of TNF-alpha plays a role in the cytotoxicity of depsipeptide against a subset of leukemias. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15515013     DOI: 10.1002/jcp.20235

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  11 in total

1.  Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Authors:  Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Journal:  Br J Haematol       Date:  2009-10-28       Impact factor: 6.998

2.  HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.

Authors:  Daniela Buglio; Noor M Khaskhely; Kui Shin Voo; Hector Martinez-Valdez; Yong-Jun Liu; Anas Younes
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

3.  Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Authors:  Sharareh Niknam; Hampartsoum B Barsoumian; Jonathan E Schoenhals; Heather L Jackson; Niranjan Yanamandra; Mauricio S Caetano; Ailin Li; Ahmed I Younes; Alexandra Cadena; Taylor R Cushman; Joe Y Chang; Quynh N Nguyen; Daniel R Gomez; Adi Diab; John V Heymach; Patrick Hwu; Maria Angelica Cortez; James W Welsh
Journal:  Clin Cancer Res       Date:  2018-05-21       Impact factor: 12.531

4.  Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

Authors:  Yasuhiko Kano; Miyuki Akutsu; Saburo Tsunoda; Tohru Izumi; Hiroyuki Kobayashi; Hiroyuki Mano; Yusuke Furukawa
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

Review 5.  TNF-α signaling in Fanconi anemia.

Authors:  Wei Du; Ozlem Erden; Qishen Pang
Journal:  Blood Cells Mol Dis       Date:  2013-07-24       Impact factor: 3.039

6.  GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses.

Authors:  Shreeram C Nallar; Sudhakar Kalakonda; Peng Sun; Dhan V Kalvakolanu
Journal:  Transl Oncogenomics       Date:  2008-03-17

7.  Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.

Authors:  Leigh Ellis; Roberto Pili
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-01

8.  RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.

Authors:  Angela M Keuling; Kathleen E A Felton; Arabesque A M Parker; Majid Akbari; Susan E Andrew; Victor A Tron
Journal:  PLoS One       Date:  2009-08-17       Impact factor: 3.240

9.  Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells.

Authors:  Anita Kumari; Ercan Cacan; Susanna F Greer; Charlie Garnett-Benson
Journal:  J Immunother Cancer       Date:  2013-09-23       Impact factor: 13.751

10.  The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells.

Authors:  Dominique N Lisiero; Horacio Soto; Richard G Everson; Linda M Liau; Robert M Prins
Journal:  J Immunother Cancer       Date:  2014-04-15       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.